ReviewSeminars in oncology
COVID-19 vaccine-related axillary lymphadenopathy in breast cancer patients: Case series with a review of literature.
Review in Seminars in oncology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 27 citations in OpenAlex.
- Not Everything That Shines Is Gold: Reactive Lymphadenopathy After COVID-19 Vaccination in a Breast Cancer Survivor.Journal of general internal medicine · 2025Article
- Reactive Axillary Lymphadenopathy Among Different COVID-19 Vaccines: A Retrospective Study in Breast Sonography.International journal of breast cancer · 2025Article
- Changes in female cancer diagnostic billing rates over the COVID-19 period in the Ontario Health Insurance Plan.Therapeutic advances in medical oncology · 2025Article
- Lymphadenopathies: A Retrospective Study of Epidemiology, Characteristics, Diagnosis and Treatment Outcomes of Patients in a Tertiary Hospital in Mogadishu-Somalia.Infection and drug resistance · 2025Article
- Role of COVID-19 Vaccine in the Management of Gynecologic Oncology Lymphadenopathies.International journal of environmental research and public health · 2024Observational
- COVID-19 vaccine-associated lymphadenopathy: a review.Le infezioni in medicina · 2024Review
- Article
- Atypical follicular hyperplasia with light chain-restricted germinal centers after COVID-19 booster: a diagnostic pitfall.Virchows Archiv : an international journal of pathology · 2023Article
- COVID-19 vaccine-induced lymphadenopathies: incidence, course and imaging features from an ultrasound prospective study.Journal of ultrasound · 2022Article
- Isolated breast parenchymal changes following COVID-19 vaccine booster.Radiology case reports · 2022Article
- Pathological Findings in COVID-19 and Non-COVID-19 Vaccine-Associated Lymphadenopathy: A Systematic Review.Journal of clinical medicine · 2022Review
- Lymphedema of the Arm after COVID-19 Vaccination in a Patient with Hidden Breast Cancer and Paraneoplastic Dermatomyositis.Vaccines · 2022Article
- COVID-19 Vaccine-Associated Lymphadenopathy in Breast Imaging Recipients: A Review of Literature.Cureus · 2022Review
- COVID-19 Vaccination in Patients with Cancer.Cancers · 2022Article
- Research trends and hotspots of breast cancer management during the COVID-19 pandemic: A bibliometric analysis.Frontiers in oncology · 2022Article
- Misdiagnosis of Reactive Lymphadenopathy Remotely After COVID-19 Vaccination: A Case Report and Literature Review.Frontiers in immunology · 2022Review
- Unilateral Axillary Lymphadenopathy in Cancer Patients Post-COVID-19 Vaccination: Review and Case Series.Case reports in oncologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeLymphadenopathy (LAP) after COVID-19 vaccination in patients with a diagnosis of cancer has been challenging. We analyzed imaging and clinical features from early cases of axillary LAP in six COVID-19 vaccine recipients with a history of breast cancer.
methodAmong the patients with a history of breast cancer and recent COVID-19 vaccine administration, six patients who showed isolated axillary LAP were gathered. Radiologic features were reviewed from breast ultrasound, chest computed tomography, and breast magnetic resonance imaging. Clinical and pathological information were obtained for analysis.
resultsThe interval between ultrasound detection of LAP and last COVID-19 vaccine administration ranged from 14 to 28 days (mean 21.67 days). Round shape of the lymph node and irregular cortex were noted in 2 and 0 cases, respectively. Mean maximum cortical thickness, length to width ratio and interval aggravation in maximum cortical thickening were 4.2 mm, 1.34, and 2.81-fold with cut-off value of 3 mm, 1.5, 2.0-fold, respectively.
conclusionWe observed axillary LAP ipsilateral to a recent vaccine administration persisting longer than what the Centers for Disease Control and Prevention announced. In our patients, COVID-19 vaccine-related LAP tended to show increased cortical thickness without cortical irregularity. Oncologist as well as radiologist should be familiar with the fact that COVID-19 vaccines, regardless of vaccine type or dosage, can frequently cause ipsilateral axillary LAP, showing some suspicious features more often than others, and can persist longer than anticipated so that both over- and underdiagnosis can be avoided. We report our observations in six patients and provide an exhaustive review of the published literature.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.